Swift B, Taneri B, Becker CM, Basarir H, Naci H, Missmer SA, Zondervan KT, Rahmioglu N. Prevalence, diagnostic delay and economic burden of endometriosis and its impact on quality of life: results from an Eastern Mediterranean population. Eur J Public Health. 2024 Apr 3;34(2):244-52. doi: 10.1093/eurpub/ckad216
Castan-Abad MT, Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Alseda M, Barbe F. Diabetes as a risk factor for severe exacerbation and death in patients with COPD: a prospective cohort study. Eur J Public Health. 2020 Aug 1;30(4):822-7. doi: 10.1093/eurpub/ckz219
Curto A, de Nazelle A, Donaire-Gonzalez D, Cole-Hunter T, Garcia-Aymerich J, Martinez D, Anaya E, Rodríguez D, Jerrett M, Nieuwenhuijsen MJ. Private and public modes of bicycle commuting: a perspective on attitude and perception. Eur J Public Health. 2016 Aug;26(4):717-23. doi: 10.1093/eurpub/ckv235
Nussbaumer B, Kaminski-Hartenthaler A, Forneris CA, Winkler D, Sonis JH, Gaynes BN, Wipplinger J, Morgan C, Greenblatt A, Lux LJ, Van Noord MG. Prevention of seasonal affective disorder-systematic review and meta-analyses. Poster presented at the 8th European Public Health Conference; October 14, 2015. Milan, Italy. [abstract] Eur J Public Health. 2015 Oct; 25(suppl_3):ckv172-08. doi: 10.1093/eurpub/ckv172.084
Maclean EN, Stone IS, Ceelen F, Garcia-Albeniz X, Sommer WH, Petersen SE. Reporting standards in cardiac MRI, CT, and SPECT diagnostic accuracy studies: analysis of the impact of STARD criteria. Eur Heart J Cardiovasc Imaging. 2014 Jun;15(6):691-700. doi: 10.1093/ehjci/jet277
Alwin J, Brodtkorb T. Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2012;13(1):25-31.
Zaniolo O, Wolowacz SE, Pradelli L. Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.
Zaniolo O, Wolowacz SE, Pradelli L. Economic performance of dabigatran etexilate for primary VTE prevention following total hip and knee replacement surgery in Italy [Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia]. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.